ReachMD
Be part of the knowledge.™Innovations in Oncology: Genitourinary Cancers
How could emerging adjuvant and neoadjuvant immunotherapy strategies transform the treatment paradigm for genitourinary (GU) cancers?
This educational series examines the current and emerging roles of immunotherapy and antibody-drug conjugates in non-muscle-invasive and muscle-invasive bladder cancer. The series also dives into strategies for selecting and sequencing immunotherapies for patients with advanced renal cell carcinoma.
Provided by:
In Partnership with:
Episodes 1-2 of 2
Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
CME/CECurrent and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
Selecting and Sequencing Immunotherapies for Patients with Advanced RCC
CME/CESelecting and Sequencing Immunotherapies for Patients with Advanced RCC
